News coverage about Oramed Pharmaceuticals (NASDAQ:ORMP) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oramed Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.1165163646386 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

Oramed Pharmaceuticals (ORMP) opened at $8.70 on Friday. Oramed Pharmaceuticals has a one year low of $5.82 and a one year high of $11.34.

A number of analysts have commented on the company. B. Riley restated a “buy” rating and issued a $20.00 price target on shares of Oramed Pharmaceuticals in a research report on Monday. ValuEngine cut Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, December 5th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Oramed Pharmaceuticals in a research report on Thursday, October 5th.

TRADEMARK VIOLATION WARNING: “Oramed Pharmaceuticals (ORMP) Receiving Somewhat Favorable News Coverage, Report Shows” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Insider Buying and Selling by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with's FREE daily email newsletter.